SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 57 filers reported holding SYNDAX PHARMACEUTICALS INC in Q4 2016. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,789,205 | +1567.5% | 192,094 | +2325.4% | 0.02% | +2000.0% |
| Q1 2023 | $167,270 | -83.4% | 7,920 | -86.3% | 0.00% | -87.5% |
| Q1 2022 | $1,005,000 | +22.1% | 57,804 | +53.7% | 0.01% | 0.0% |
| Q4 2021 | $823,000 | +162.9% | 37,598 | +129.4% | 0.01% | +100.0% |
| Q3 2021 | $313,000 | -13.8% | 16,393 | -22.6% | 0.00% | 0.0% |
| Q2 2021 | $363,000 | -3.2% | 21,166 | +26.4% | 0.00% | -20.0% |
| Q1 2021 | $375,000 | -51.0% | 16,751 | -51.4% | 0.01% | -54.5% |
| Q4 2020 | $766,000 | +571.9% | 34,447 | +347.4% | 0.01% | +450.0% |
| Q3 2020 | $114,000 | -50.2% | 7,700 | -50.2% | 0.00% | -50.0% |
| Q2 2020 | $229,000 | +1247.1% | 15,461 | +621.1% | 0.00% | +300.0% |
| Q3 2018 | $17,000 | +6.2% | 2,144 | +78.7% | 0.00% | 0.0% |
| Q1 2017 | $16,000 | -15.8% | 1,200 | -55.0% | 0.00% | -50.0% |
| Q4 2016 | $19,000 | – | 2,666 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 1,025,000 | $24,631,000 | 16.36% |
| Kynam Capital Management, LP | 2,272,915 | $54,618,000 | 11.51% |
| Frazier Life Sciences Management, L.P. | 3,412,838 | $82,010,000 | 6.32% |
| Foresite Capital Management IV, LLC | 690,000 | $16,581,000 | 5.33% |
| Paradigm Biocapital Advisors LP | 1,085,142 | $26,076,000 | 3.48% |
| ACUTA CAPITAL PARTNERS, LLC | 324,614 | $7,800,000 | 3.36% |
| COMMODORE CAPITAL LP | 738,110 | $17,737,000 | 2.85% |
| SPHERA FUNDS MANAGEMENT LTD. | 822,696 | $19,769,000 | 2.74% |
| Avidity Partners Management LP | 5,586,900 | $134,253,000 | 2.73% |
| HealthCor Management, L.P. | 859,240 | $20,648,000 | 2.58% |